The stomach cancer market is anticipated to expand from US$ 3,575.04 million in 2022 to US$ 10,751.42 million by 2030, reflecting a compound annual growth rate (CAGR) of 14.8% over the period from 2022 to 2030.

Several key factors are propelling this market growth, including the rising incidence of stomach cancer, advancements in treatment modalities such as chemotherapy, surgical interventions, and targeted therapies, as well as ongoing research and development aimed at enhancing patient outcomes. The increasing focus on early detection and personalized treatment strategies is expected to further drive the expansion of the stomach cancer treatment market in the coming years.

Stomach cancer, or gastric cancer, arises from the abnormal proliferation of malignant cells within the stomach. Various risk factors contribute to the likelihood of developing stomach cancer, including age and dietary habits. Symptoms associated with stomach cancer can include indigestion, discomfort in the stomach, loss of appetite, heartburn, and unintended weight loss. Treatment options for stomach cancer encompass chemotherapy, radiation therapy, and immunotherapy.

The Growing Incidence of Stomach Cancer Fuels Market Expansion

Stomach cancer is recognized as a significant global health concern. The stomach's inner lining, which consists of a mucous membrane made up of cells and glands, can undergo pre-cancerous changes before actual cancer develops. Inflammation of these cells can lead to peptic ulcers, which may progress to gastric cancer. Early indicators of gastric cancer include nausea, indigestion, loss of appetite, and heartburn, while advanced stages may present with symptoms such as jaundice, abdominal pain, stomach swelling, blood in stools, vomiting, constipation, and significant weight loss. Despite a decline in incidence and mortality rates over recent decades, stomach cancer remains a critical health issue worldwide.

Globally, gastric cancer ranks as the fifth most prevalent cancer and was the fourth leading cause of cancer-related deaths in both sexes combined in 2020. According to the Global Cancer Statistics 2020 report by GLOBOCAN, approximately 1.1 million cases of gastric cancer were diagnosed in 2020, comprising 720,000 males and 370,000 females, which accounted for 5.6% of all cancer cases. The disease resulted in around 800,000 fatalities, representing 7.7% of all cancer deaths that year. The highest incidence rates were observed in Eastern Asia and Eastern Europe, with men accounting for about two-thirds of all cases.

Consequently, the increasing prevalence of stomach cancer necessitates a variety of treatment options, thereby driving the growth of the stomach cancer market.

Industry Developments and Future Prospects

Several initiatives by key players in the global stomach cancer market are noteworthy:

In January 2021, AstraZeneca and Daiichi Sankyo Company received FDA approval for Enhertu, a treatment for adult patients with advanced or metastatic HER2-positive gastric adenocarcinoma.

Additionally, the surge in clinical trials aimed at developing effective therapies for gastric cancer, along with a rise in product launches and regulatory approvals, is expected to stimulate market growth. For instance, in April 2021, the FDA approved Bristol Myers Squibb's Opdivo in combination with fluoropyrimidine and platinum-based chemotherapy for patients with advanced or metastatic gastric cancer and esophageal adenocarcinoma. Such developments are likely to bolster market growth during the forecast period.

Segmental Analysis

The stomach cancer market is segmented by type into adenocarcinomas, gastrointestinal stromal tumors, neuroendocrine tumors, lymphoma, and others. The adenocarcinomas segment held a substantial market share in 2022 and is projected to exhibit the highest CAGR from 2022 to 2030.

In terms of treatment, the market is divided into targeted and immunotherapy drugs, chemotherapy and combination therapies, and others. In 2022, the chemotherapy and combination drugs segment captured a significant market share, while the targeted and immunotherapy drugs segment is expected to achieve the highest CAGR during the forecast period.

Regarding the route of administration, the stomach cancer market is categorized into oral, parenteral, and other methods. The oral segment held a considerable market share in 2022 and is predicted to experience the fastest CAGR from 2022 to 2030.

Finally, by distribution channel, the market is segmented into hospital, retail, and online pharmacies. The hospital pharmacies segment accounted for a significant share in 2022 and is anticipated to register the highest CAGR during the forecast period.